Cim LLC Sells 8,593 Shares of Novo Nordisk A/S (NYSE:NVO)

Cim LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,823 shares of the company's stock after selling 8,593 shares during the period. Novo Nordisk A/S comprises approximately 2.6% of Cim LLC's holdings, making the stock its 17th biggest position. Cim LLC's holdings in Novo Nordisk A/S were worth $18,221,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in NVO. BridgePort Financial Solutions LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $540,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $29,000. Employees Retirement System of Texas raised its position in shares of Novo Nordisk A/S by 9.9% during the 4th quarter. Employees Retirement System of Texas now owns 72,964 shares of the company's stock worth $6,276,000 after buying an additional 6,560 shares in the last quarter. Brucke Financial Inc. acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $542,000. Finally, Carolinas Wealth Consulting LLC grew its stake in shares of Novo Nordisk A/S by 920.6% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 1,092 shares of the company's stock worth $94,000 after purchasing an additional 985 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO traded up $1.83 during mid-day trading on Friday, hitting $71.29. The company's stock had a trading volume of 7,181,287 shares, compared to its average volume of 6,756,588. The firm has a market capitalization of $319.92 billion, a PE ratio of 21.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The stock's 50-day moving average is $65.63 and its two-hundred day moving average is $82.01. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.